FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387498051> ?p ?o ?g. }

• W4387498051 abstract "Chimeric antigen receptor NK (CAR-NK) cell therapy is one of the most promising immunotherapies. Although it has shown a significant therapeutic effect in hematologic malignancies, few successes have been obtained in solid tumors including esophageal squamous cell carcinoma (ESCC). The major reasons are lack of specific cell surface antigens and complex tumor microenvironment. Here we identify CD22, a well-known tumor surface marker in hematologic malignancies, is expressed in ESCC, possibly serving as a potential target of CAR-NK cell therapy.The expression of 13 tumor cell surface antigens used clinically was analyzed in patients from The Cancer Genome Atlas (TCGA) database. Also, mRNA expression were detected in 2 ESCC cell lines and 2 patients samples by qCPR. Then according to Venn diagram, CD22 was selected for further investigation. Following this, the expression of CD22 by immunofluorescence (IF) in ESCC cell lines and by immunohistochemistry (IHC) in 87 cases of human ESCC samples was detected respectively. On the basis of H-score results, the correlation between CD22 expression and clinical parameters was analyzed. As a proof, the efficacy of CD22-targeted CAR-NK cells against ESCC cell lines was performed by a real-time cell analyzer (RTCA) platform.KYSE-140 and KYSE-150 cell lines displayed surface expression of CD22. IHC showed an 80.46% (70/87) positive rate in ESCC patient samples. Among these, cell membranous expression of CD22 was observed in 27.59% (24/87) patient samples. Through chi-square test, expression of CD22 in ESCC was associated with lymph node metastasis while it was no related to the depth of tumor invasion and clinical stage. Engineered CD22-targeted CAR-NK cells exhibited inhibitory growth capability against ESCC cell lines (p < 0.0001).CD22 is a potential tumor surface antigen capable of being targeted by CAR-NK cells in ESCC. And potential therapeutics for ESCC may be developed based on immune cells expressing anti-CD22 CAR. The study also indicates that CD22 CAR-NK cells could be used in other cancers and more in vivo experiments are needed." @default.
• W4387498051 created "2023-10-11" @default.
• W4387498051 creator A5001341296 @default.
• W4387498051 creator A5009951600 @default.
• W4387498051 creator A5014465282 @default.
• W4387498051 creator A5021803950 @default.
• W4387498051 creator A5025062638 @default.
• W4387498051 creator A5034250004 @default.
• W4387498051 creator A5037562981 @default.
• W4387498051 creator A5044041652 @default.
• W4387498051 creator A5057567182 @default.
• W4387498051 creator A5080230572 @default.
• W4387498051 creator A5080239408 @default.
• W4387498051 date "2023-10-10" @default.
• W4387498051 modified "2023-10-12" @default.
• W4387498051 title "CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinoma" @default.
• W4387498051 cites W1965258774 @default.
• W4387498051 cites W1989566870 @default.
• W4387498051 cites W2034748674 @default.
• W4387498051 cites W2092166052 @default.
• W4387498051 cites W2098372175 @default.
• W4387498051 cites W2113876228 @default.
• W4387498051 cites W2150235363 @default.
• W4387498051 cites W2167255318 @default.
• W4387498051 cites W2302851559 @default.
• W4387498051 cites W2419127460 @default.
• W4387498051 cites W2766187664 @default.
• W4387498051 cites W2810715813 @default.
• W4387498051 cites W2914996705 @default.
• W4387498051 cites W2946567117 @default.
• W4387498051 cites W2948485623 @default.
• W4387498051 cites W2951744765 @default.
• W4387498051 cites W3004611567 @default.
• W4387498051 cites W3018483431 @default.
• W4387498051 cites W3020949066 @default.
• W4387498051 cites W3021971416 @default.
• W4387498051 cites W3043066048 @default.
• W4387498051 cites W3080714131 @default.
• W4387498051 cites W3092352594 @default.
• W4387498051 cites W3108226967 @default.
• W4387498051 cites W3113146435 @default.
• W4387498051 cites W3128646645 @default.
• W4387498051 cites W3158106454 @default.
• W4387498051 cites W3163599487 @default.
• W4387498051 cites W3201853605 @default.
• W4387498051 cites W4200201081 @default.
• W4387498051 cites W4210685329 @default.
• W4387498051 cites W4247718910 @default.
• W4387498051 cites W4280638672 @default.
• W4387498051 cites W4295749231 @default.
• W4387498051 cites W4317812706 @default.
• W4387498051 cites W4319442266 @default.
• W4387498051 cites W4324009731 @default.
• W4387498051 cites W4353015048 @default.
• W4387498051 doi "https://doi.org/10.1186/s12967-023-04409-8" @default.
• W4387498051 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37817249" @default.
• W4387498051 hasPublicationYear "2023" @default.
• W4387498051 type Work @default.
• W4387498051 citedByCount "0" @default.
• W4387498051 crossrefType "journal-article" @default.
• W4387498051 hasAuthorship W4387498051A5001341296 @default.
• W4387498051 hasAuthorship W4387498051A5009951600 @default.
• W4387498051 hasAuthorship W4387498051A5014465282 @default.
• W4387498051 hasAuthorship W4387498051A5021803950 @default.
• W4387498051 hasAuthorship W4387498051A5025062638 @default.
• W4387498051 hasAuthorship W4387498051A5034250004 @default.
• W4387498051 hasAuthorship W4387498051A5037562981 @default.
• W4387498051 hasAuthorship W4387498051A5044041652 @default.
• W4387498051 hasAuthorship W4387498051A5057567182 @default.
• W4387498051 hasAuthorship W4387498051A5080230572 @default.
• W4387498051 hasAuthorship W4387498051A5080239408 @default.
• W4387498051 hasBestOaLocation W43874980511 @default.
• W4387498051 hasConcept C111700020 @default.
• W4387498051 hasConcept C121608353 @default.
• W4387498051 hasConcept C126322002 @default.
• W4387498051 hasConcept C143998085 @default.
• W4387498051 hasConcept C1491633281 @default.
• W4387498051 hasConcept C18031839 @default.
• W4387498051 hasConcept C204232928 @default.
• W4387498051 hasConcept C2781230642 @default.
• W4387498051 hasConcept C502942594 @default.
• W4387498051 hasConcept C54355233 @default.
• W4387498051 hasConcept C71924100 @default.
• W4387498051 hasConcept C86803240 @default.
• W4387498051 hasConceptScore W4387498051C111700020 @default.
• W4387498051 hasConceptScore W4387498051C121608353 @default.
• W4387498051 hasConceptScore W4387498051C126322002 @default.
• W4387498051 hasConceptScore W4387498051C143998085 @default.
• W4387498051 hasConceptScore W4387498051C1491633281 @default.
• W4387498051 hasConceptScore W4387498051C18031839 @default.
• W4387498051 hasConceptScore W4387498051C204232928 @default.
• W4387498051 hasConceptScore W4387498051C2781230642 @default.
• W4387498051 hasConceptScore W4387498051C502942594 @default.
• W4387498051 hasConceptScore W4387498051C54355233 @default.
• W4387498051 hasConceptScore W4387498051C71924100 @default.
• W4387498051 hasConceptScore W4387498051C86803240 @default.
• W4387498051 hasIssue "1" @default.
• W4387498051 hasLocation W43874980511 @default.
• W4387498051 hasLocation W43874980512 @default.
• W4387498051 hasOpenAccess W4387498051 @default.

• next